RS62383B1 - Stabilna farmaceutska kompozicija sa fiksnom dozom koja sadrži mometazon i olopatadin za nazalnu primenu - Google Patents

Stabilna farmaceutska kompozicija sa fiksnom dozom koja sadrži mometazon i olopatadin za nazalnu primenu

Info

Publication number
RS62383B1
RS62383B1 RS20211201A RSP20211201A RS62383B1 RS 62383 B1 RS62383 B1 RS 62383B1 RS 20211201 A RS20211201 A RS 20211201A RS P20211201 A RSP20211201 A RS P20211201A RS 62383 B1 RS62383 B1 RS 62383B1
Authority
RS
Serbia
Prior art keywords
pharmaceutical composition
olopatadine
mometasone
composition according
suspension
Prior art date
Application number
RS20211201A
Other languages
English (en)
Serbian (sr)
Inventor
Ulhas Dhuppad
Ashok Katkurwar
Yashwant Gupta
Rajesh Ankam
Chandrakant Dhatrak
Original Assignee
Glenmark Specialty Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=51688369&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RS62383(B1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Glenmark Specialty Sa filed Critical Glenmark Specialty Sa
Publication of RS62383B1 publication Critical patent/RS62383B1/sr

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/10Dispersions; Emulsions
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/335Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/55Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having seven-membered rings, e.g. azelastine, pentylenetetrazole
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/56Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/58Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids containing heterocyclic rings, e.g. danazol, stanozolol, pancuronium or digitogenin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/02Inorganic compounds
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/26Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/30Macromolecular organic or inorganic compounds, e.g. inorganic polyphosphates
    • A61K47/36Polysaccharides; Derivatives thereof, e.g. gums, starch, alginate, dextrin, hyaluronic acid, chitosan, inulin, agar or pectin
    • A61K47/38Cellulose; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00Medicinal preparations characterised by special physical form
    • A61K9/0012Galenical forms characterised by the site of application
    • A61K9/0043Nose
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/02Nasal agents, e.g. decongestants
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/14Decongestants or antiallergics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/08Antiallergic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00Drugs for disorders of the endocrine system
    • A61P5/38Drugs for disorders of the endocrine system of the suprarenal hormones
    • A61P5/44Glucocorticosteroids; Drugs increasing or potentiating the activity of glucocorticosteroids

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Inorganic Chemistry (AREA)
  • Otolaryngology (AREA)
  • Pulmonology (AREA)
  • Dispersion Chemistry (AREA)
  • Immunology (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Diabetes (AREA)
  • Endocrinology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
RS20211201A 2013-09-13 2014-09-04 Stabilna farmaceutska kompozicija sa fiksnom dozom koja sadrži mometazon i olopatadin za nazalnu primenu RS62383B1 (sr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
IN2975MU2013 2013-09-13
EP14781946.0A EP3043773B1 (en) 2013-09-13 2014-09-04 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine for nasal administration
PCT/IB2014/064251 WO2015036902A1 (en) 2013-09-13 2014-09-04 Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine

Publications (1)

Publication Number Publication Date
RS62383B1 true RS62383B1 (sr) 2021-10-29

Family

ID=51688369

Family Applications (1)

Application Number Title Priority Date Filing Date
RS20211201A RS62383B1 (sr) 2013-09-13 2014-09-04 Stabilna farmaceutska kompozicija sa fiksnom dozom koja sadrži mometazon i olopatadin za nazalnu primenu

Country Status (23)

Country Link
US (1) US9078923B2 (enExample)
EP (2) EP3043773B1 (enExample)
JP (2) JP6203967B2 (enExample)
BR (1) BR112015018252B1 (enExample)
CY (1) CY1124675T1 (enExample)
DK (1) DK3043773T3 (enExample)
ES (1) ES2891729T3 (enExample)
FR (1) FR21C1057I2 (enExample)
HR (1) HRP20211515T1 (enExample)
HU (1) HUE056448T2 (enExample)
LT (1) LT3043773T (enExample)
MX (1) MX367674B (enExample)
MY (1) MY191380A (enExample)
NL (1) NL301154I2 (enExample)
NO (1) NO2021045I1 (enExample)
PH (1) PH12016500433B1 (enExample)
PL (1) PL3043773T3 (enExample)
PT (1) PT3043773T (enExample)
RS (1) RS62383B1 (enExample)
SI (1) SI3043773T1 (enExample)
SM (1) SMT202100563T1 (enExample)
UA (1) UA116793C2 (enExample)
WO (1) WO2015036902A1 (enExample)

Families Citing this family (19)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6203967B2 (ja) * 2013-09-13 2017-09-27 グレンマーク・スペシャルティー・エスエー モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物
US9937189B2 (en) 2013-09-13 2018-04-10 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US9370483B2 (en) * 2013-09-13 2016-06-21 Glenmark Specialty S.A. Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10548907B2 (en) 2013-10-04 2020-02-04 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10653661B2 (en) 2013-10-04 2020-05-19 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10758550B2 (en) 2013-10-04 2020-09-01 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
US10016443B2 (en) 2013-10-04 2018-07-10 Glenmark Specialty S.A. Treatment of allergic rhinitis using a combination of mometasone and olopatadine
RU2686670C2 (ru) 2013-10-04 2019-04-30 Гленмарк Спешиалити С.А. Лечение аллергического ринита с использованием комбинации мометазона и олопатадина
US11679210B2 (en) 2014-10-03 2023-06-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2016155021A1 (zh) 2015-04-03 2016-10-06 绿仕科技控股有限公司 环境控制系统
EP3468532B1 (en) * 2017-06-28 2020-09-23 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
TWI790316B (zh) * 2017-12-14 2023-01-21 瑞士商葛蘭馬克專業股份公司 用於向人類經鼻投與之含有水性醫藥組合物的分配裝置
US12303635B2 (en) 2018-04-16 2025-05-20 Glenmark Specialty S.A. Dispensing device and pharmaceutical composition for the treatment of rhinitis
WO2020070599A1 (en) * 2018-10-05 2020-04-09 Glenmark Specialty S.A. Nebulization composition of mometasone
CN109602693A (zh) * 2018-11-13 2019-04-12 华润三九(南昌)药业有限公司 糠酸莫米松凝胶及其制备方法
TW202133860A (zh) * 2019-12-06 2021-09-16 日商東興藥品工業股份有限公司 含有類固醇化合物及歐羅派特錠的醫藥組成物
CA3181959A1 (en) * 2020-06-15 2021-12-23 Alkem Laboratories Limited Combination of alcaftadine and a corticosteroid
PE20251774A1 (es) * 2023-11-21 2025-07-14 Glenmark Specialty Sa Composicion de aerosol nasal
WO2025137749A1 (pt) * 2023-12-27 2025-07-03 Eurofarma Laboratórios S.A. Processo de solubilização de olopatadina e seu uso

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4923892A (en) 1985-08-17 1990-05-08 Burroughs Wellcome Co. Tricyclic aromatic compounds
GB8520662D0 (en) 1985-08-17 1985-09-25 Wellcome Found Tricyclic aromatic compounds
US6127353A (en) 1991-09-06 2000-10-03 Schering Corporation Mometasone furoate monohydrate, process for making same and pharmaceutical compositions
US5837699A (en) 1994-01-27 1998-11-17 Schering Corporation Use of mometasone furoate for treating upper airway passage diseases
WO2001026658A2 (en) * 1999-10-08 2001-04-19 Schering Corporation Topical nasal treatment using desloratadine
US7977376B2 (en) 2001-06-27 2011-07-12 Novartis Ag Olopatadine formulations for topical nasal administration
GB2389530B (en) 2002-06-14 2007-01-10 Cipla Ltd Pharmaceutical compositions
MXPA05005044A (es) * 2002-11-12 2005-07-01 Alcon Inc El uso de un agente antialergico y un esteroide para tratar rinitis alergica.
US8912174B2 (en) * 2003-04-16 2014-12-16 Mylan Pharmaceuticals Inc. Formulations and methods for treating rhinosinusitis
CA2586553C (en) 2004-11-24 2015-02-10 Alcon, Inc. Nasal sprayer containing a formulation with olopatadine
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
CA2631757A1 (en) * 2005-12-02 2007-06-07 Elan Pharma International Limited Novel mometasone compositions and methods of making and using the same
AR059358A1 (es) * 2006-02-09 2008-03-26 Schering Corp Formulaciones farmaceuticas
GB0615108D0 (en) * 2006-07-28 2006-09-06 Glaxo Group Ltd Novel formulations
AU2007311607A1 (en) 2006-10-19 2008-04-24 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
CN101795565A (zh) * 2007-06-28 2010-08-04 锡德克斯药物公司 皮质类固醇水溶液的鼻部和眼部给药
US8642069B2 (en) 2008-08-27 2014-02-04 Alexander D. Goldin Composition and method for treating colds
AR073796A1 (es) * 2008-10-10 2010-12-01 Schering Corp Formulaciones de corticosteroides y sus metodos de tratamiento
WO2011141929A2 (en) 2010-05-11 2011-11-17 Cadila Healthcare Limited Aqueous pharmaceutical compositions of fluticasone and olopatadine
KR101261230B1 (ko) * 2010-11-29 2013-05-07 한림제약(주) 모메타손 푸로에이트 및 아젤라스틴 염산염을 포함하는 비내 투여용 약학 조성물
ES2626134T3 (es) * 2011-01-04 2017-07-24 Bausch & Lomb Incorporated Composiciones de bepotastina
FR2970180B1 (fr) 2011-01-06 2013-08-02 Substipharm Dev Procede de preparation de suspensions aqueuses pharmaceutiques comprenant un medicament efficace dans le traitement des rhinites
KR20140081925A (ko) 2012-12-12 2014-07-02 한미약품 주식회사 코르티코스테로이드, 항히스타민제 및 스테비아를 포함하는 고미 차폐된 약학 제제
JP6203967B2 (ja) * 2013-09-13 2017-09-27 グレンマーク・スペシャルティー・エスエー モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物

Also Published As

Publication number Publication date
RU2015128497A3 (enExample) 2018-05-11
MX2015013965A (es) 2016-02-10
EP3043773B1 (en) 2021-06-30
HUE056448T2 (hu) 2022-02-28
CY1124675T1 (el) 2022-07-22
JP6664358B2 (ja) 2020-03-13
PT3043773T (pt) 2021-10-04
DK3043773T3 (da) 2021-10-04
JP2016534142A (ja) 2016-11-04
US9078923B2 (en) 2015-07-14
SMT202100563T1 (it) 2021-11-12
NO2021045I1 (no) 2021-10-22
FR21C1057I1 (fr) 2022-01-21
BR112015018252A2 (pt) 2017-07-18
PL3043773T3 (pl) 2021-12-13
ES2891729T3 (es) 2022-01-31
JP6203967B2 (ja) 2017-09-27
EP3043773A1 (en) 2016-07-20
US20150079178A1 (en) 2015-03-19
MX367674B (es) 2019-08-30
NL301154I2 (nl) 2022-07-18
RU2015128497A (ru) 2017-10-18
BR112015018252B1 (pt) 2023-01-10
RU2687551C2 (ru) 2019-05-15
UA116793C2 (uk) 2018-05-10
PH12016500433A1 (en) 2016-05-16
PH12016500433B1 (en) 2023-03-01
HRP20211515T1 (hr) 2021-12-24
WO2015036902A1 (en) 2015-03-19
JP2017206560A (ja) 2017-11-24
MY191380A (en) 2022-06-21
FR21C1057I2 (fr) 2023-02-03
LT3043773T (lt) 2021-10-11
SI3043773T1 (sl) 2021-12-31
EP3718533A1 (en) 2020-10-07

Similar Documents

Publication Publication Date Title
JP6664358B2 (ja) モメタゾン及びオロパタジンを有する安定な定用量薬剤組成物
US9750754B2 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
US10376526B2 (en) Stable fixed dose pharmaceutical composition comprising mometasone and olopatadine
RS58377B1 (sr) Kompozicije koje sadrže azelastin i metode njihove upotrebe
US20170333449A1 (en) Treatment of allergic rhinitis using a combination of mometasone and olopatadine
KR102709429B1 (ko) 모메타손 및 올로파타딘의 조합을 사용하는 소아 대상체의 알레르기성 비염의 치료
RU2798030C2 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина
WO2024079676A1 (en) Novel nasal spray assembling process
HK40033829A (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
HK40033829B (en) Treatment of allergic rhinitis in pediatric subjects using a combination of mometasone and olopatadine
EA047266B1 (ru) Лечение аллергического ринита у субъектов детской возрастной категории с применением комбинации мометазона и олопатадина